US2015141435A1PendingUtilityA1
2-pyridone antimicrobial compositions

Assignee: Emergent BioSolutionsPriority: Sep 27, 2010Filed: Jan 7, 2015Published: May 21, 2015
Est. expirySep 27, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Patrick Roussel Jutta Heim Peter Schneider Christian Bartels Yaoquan Liu Glen Dale Daniel Milligan
A61P 31/04C07D 455/02A61K 31/496A61K 31/444A61K 31/4375A61K 31/4709Y02A50/30
PatentIndex Score
Cited by
References
Claims
Abstract

Disclosed herein are compounds of Formula I wherein R 1 , R 2 , X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.
Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for treating an infection comprising, providing to a patient infected by a pathogen selected from the group consisting of  Acinetobacter baumannii, Bacillus anthracis, Brucella abortus, Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia thailandensis, Citrobacter freundii, Corynebacterium jeikeium, Enterobacter  sp,  Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Enterococcus gallinarum, Escherichia coli, Francisella tularensis, Haemophilus influenza, Klebsiella aerogenes, Klebsiella pneumoniae, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria meningitides, Proteus mirabilis, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Shigella  sp,  Staphylococcus aureus, Staphylococcus epidermis, Staphylococcus haemolyticus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus bovis, Streptococcus constellatus, Streptococcus mitis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus oralis, Streptococcus sanguis , Group C  Streptococcus, Yersinia pestis , and drug-resistant strains thereof, a therapeutically effective amount of a compound of the formula, 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         R 1  is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8  haloalkyl, heterocyclyl, —OR 11 , —N(R 11 ) 2 , or —C(O)N(R 11 ) 2 , wherein each R 11  is independently hydrogen, C 1-8  alkyl, or C 1-8  haloalkyl; 
         R 2  is a C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, or heteroaryl, wherein the cycloalkyl and heteroaryl are optionally substituted with one to five groups that are each independently halogen, C 1-8  alkyl, —OR 21 , —N(R 21 ) 2 , or —C(O)OR 21 , wherein each R 21  is independently hydrogen or C 1-8  alkyl; 
         Y is heterocyclyl, aryl, or heteroaryl, each optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y , wherein 
         R Y  is nitro, cyano, —OR Y1 , —SR Y1 , —N(R Y1 ) 2 , —C(O)R Y1 , —C(O)OR Y1 , —C(O)N(R Y1 ) 2 , —OC(O)R Y1 , —OC(O)OR Y1 , —OC(O)N(R Y1 ) 2 , —N(R Y1 )C(O)R Y1 , —N(R Y1 )C(O)OR Y1 , —N(R Y1 )C(O)N(R Y1 ) 2 , —S(O) 2 R Y1 , —S(O) 2 OR Y1 , —S(O) 2 N(R Y1 ) 2 , —OS(O) 2 R Y1 , —OS(O) 2 OR Y1 , —OS(O) 2 N(R Y1 ) 2 , —N(R Y1 )S(O) 2 R Y1 , —N(R Y1 )S(O) 2 OR Y1 , or —N(R Y1 )S(O) 2 N(R Y1 ) 2 , wherein each R 1  is independently hydrogen, C 1-8  alkyl, or C 1-8  haloalkyl; and 
         X is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8 haloalkyl, —OR X , —N(R X ) 2 , —C(O)R X , —C(O)OR X , or —C(O)N(R X ) 2 , wherein each R X  is independently hydrogen, C 1-8  alkyl, or C 1-8 haloalkyl. 
       
     
     
         2 . The method of  claim 1 , wherein R 1  is hydrogen, halogen, or C 1-8  alkyl. 
     
     
         3 . The method of  claim 1 , wherein the compound is of one of the formulas, 
       
         
           
           
               
               
           
         
       
     
     
         4 . The method of any one of  claims 1 - 3 , wherein X is hydrogen or halogen. 
     
     
         5 . The method of any one of  claims 1 - 4 , wherein
 Y is aryl optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y .   
     
     
         6 . The method of any one of  claims 1 - 4 , wherein Y is heteroaryl optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y . 
     
     
         7 . The method of any one of  claims 1 - 4 , wherein Y is a bicyclic heteroaryl optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y . 
     
     
         8 . The method of  claim 1 , wherein the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-5-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-chloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methoxy-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-acetamido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-sulfonamido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-methylamino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methyl-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-ureido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-dimethylamino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-dichloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-chloro-4-amino-5-methyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-toluyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(piperazin-1-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-amino-1-piperidyl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2,5-difluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-cyano-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-pyrrol-3-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-chloro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-methoxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxymethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-2-oxo-3,4-dihydro-1H-quinolin-7-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[5-(aminomethyl)-2-furyl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-cyano-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         9 . The method of  claim 1 , wherein the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         10 . The method of any one of  claims 1 - 9 , wherein the pathogen is  Burkholderia mallei, Burkholderia pseudomallei, Bacillus anthracis, Francisella tularensis, Yersinia pestis , or  Brucella abortus.    
     
     
         11 . The method of any one of  claims 1 - 9 , wherein the pathogen is selected from the group consisting of,
 (a)  Acinetobacter baumannii, Bacillus anthracis, Brucella abortus, Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia thailandensis, Citrobacter freundii, Corynebacterium jeikeium, Enterobacter  sp,  Enterobacter cloacae, Enterococcus faecium, Enterococcus gallinarum, Francisella tularensis, Klebsiella aerogenes, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria meningitides, Proteus mirabilis, Providencia stuartii, Serratia marcescens, Shigella  sp,  Staphylococcus haemolyticus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus bovis, Streptococcus constellatus, Streptococcus mitis, Streptococcus pyogenes, Streptococcus oralis, Streptococcus sanguis , Group C  Streptococcus , and  Yersinia pestis,      (b) drug-resistant strains of any pathogen of part (a); and   (c) and drug-resistant strains of  Staphylococcus aureus, Staphylococcus epidermis, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa , and  Haemophilus  influenza.   
     
     
         12 . The method of any one of  claims 1 - 9 , wherein the pathogen is selected from the group consisting of  Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Stenotrophomonas maltophilia, Streptococcus pneumoniae , and drug-resistant strains thereof. 
     
     
         13 . The method of  claim 1 , wherein the pathogen is selected from the group consisting of  Burkholderia cepacia, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus , and drug-resistant strains thereof; and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         14 . The method of  claim 1 , wherein the pathogen is selected from the group consisting of  Burkholderia mallei, Burkholderia pseudomallei, Bacillus anthracis, Yersinia pestis, Francisella tularensis , and  Brucella abortus , and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-5-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-chloro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxymethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         15 . The method of  claim 1 , wherein the pathogen is selected from the group consisting of  Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Burkholderia cepacia, Haemophilus influenzae, Acinetobacter baumannii , and drug resistant strains thereof; and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         16 . The method of  claim 1 , wherein the pathogen is selected from the group consisting of  Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus saprophyticus, Enterococcus faecalis, Enterococcus faecium, Enterococcus gallinarum, Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus agalactiae , Group C  Streptococcus, Streptococcus mitis, Streptococcus constellatus, Streptococcus oralis, Streptococcus bovis, Streptococcus sanguis, Corynebacterium jeikeium, Listeria monocytogenes, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Enterobacter  sp,  Serratia marcescens, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia, Proteus mirabilis, Shigella  sp,  Morganella morganii, Providencia stuartii, Neisseria meningitides, Haemophilus influenza, Moraxella catarrhalis, Acinetobacter baumannii, Citrobacter freundii , and drug resistant strains thereof; and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         17 . The method of  claim 1 , wherein the pathogen is selected from the group consisting of  Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Burkholderia cepacia, Haemophilus influenzae, Acinetobacter baumannii , and drug resistant strains thereof; and the compound is
 8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         18 . The method of  claim 1 , wherein the pathogen is Methicillin-resistant  Staphylococcus aureus  and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         19 . The method of any one of  claims 1 - 18 , wherein the compound is a pharmaceutically acceptable salt, and the pharmaceutically acceptable salt is a potassium salt. 
     
     
         20 . Use of a compound of the formula, 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         R 1  is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8  haloalkyl, heterocyclyl, —OR 11 , —N(R 11 ) 2 , or —C(O)N(R 11 ) 2 , wherein each R 11  is independently hydrogen, C 1-8  alkyl, or C 1-8  haloalkyl; 
         R 2  is a C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, or heteroaryl, wherein the cycloalkyl and heteroaryl are optionally substituted with one to five groups that are each independently halogen, C 1-8  alkyl, —OR 21 , —N(R 21 ) 2 , or —C(O)OR 21 , wherein each R 21  is independently hydrogen or C 1-8  alkyl; 
         Y is heterocyclyl, aryl, or heteroaryl, each optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y , wherein 
         R Y  is nitro, cyano, —OR Y1 , —SR Y1 , —N(R Y1 ) 2 , —C(O)R Y1 , —C(O)OR Y1 , —C(O)N(R Y1 ) 2 , —OC(O)R Y1 , —OC(O)OR Y1 , —OC(O)N(R Y1 ) 2 , —N(R Y1 )C(O)R Y1 , —N(R Y1 )C(O)OR Y1 , —N(R Y1 )C(O)N(R Y1 ) 2 , —S(O) 2 R Y1 , —S(O) 2 OR Y1 , —S(O) 2 N(R Y1 ) 2 , —OS(O) 2 R Y1 , —OS(O) 2 OR Y1 , —OS(O) 2 N(R Y1 ) 2 , —N(R Y1 )S(O) 2 R Y1 , —N(R Y1 )S(O) 2 OR Y1 , or —N(R Y1 )S(O) 2 N(R Y1 ) 2 , wherein each R Y1  is independently hydrogen, C 1-8  alkyl, or C 1-8  haloalkyl; and 
         X is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8 haloalkyl, —O(R X ), —N(R X ) 2 , —C(O)R X , —C(O)OR X , or —C(O)N(R X ) 2 , wherein each R X  is independently hydrogen, C 1-8  alkyl, or C 1-8 haloalkyl, 
         for the preparation of a medicament for treating an infection caused by a pathogen selected from the group consisting of  Burkholderia mallei, Burkholderia pseudomallei, Burkholderia cepacia, Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella abortus, Burkholderia thailandensis, Acinetobacter baumannii, Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus epidermis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus , and drug-resistant strains thereof. 
       
     
     
         21 . Use of  claim 20 , wherein R 1  is hydrogen, halogen, or C 1-8  alkyl. 
     
     
         22 . Use of  claim 20 , wherein the compound is of one of the formulas, 
       
         
           
           
               
               
           
         
       
     
     
         23 . Use of any one of  claims 20 - 22 , wherein X is hydrogen or halogen. 
     
     
         24 . Use of any one of  claims 20 - 23 , wherein
 Y is aryl optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y .   
     
     
         25 . Use of any one of  claims 20 - 23 , wherein Y is heteroaryl optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y . 
     
     
         26 . Use of any one of  claims 20 - 23 , wherein Y is a bicyclic heteroaryl optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y . 
     
     
         27 . Use of  claim 20 , wherein the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-5-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-chloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methoxy-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-acetamido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-sulfonamido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-methylamino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methyl-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-ureido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-dimethylamino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-dichloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-chloro-4-amino-5-methyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-toluyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(piperazin-1-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-amino-1-piperidyl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2,5-difluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-cyano-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-pyrrol-3-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-chloro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-methoxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxymethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-2-oxo-3,4-dihydro-1H-quinolin-7-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[5-(aminomethyl)-2-furyl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-cyano-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         28 . Use of  claim 20 , wherein the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         29 . Use of any one of  claims 20 - 28 , wherein the pathogen is  Burkholderia mallei, Burkholderia pseudomallei, Bacillus anthracis, Francisella tularensis, Yersinia pestis , or  Brucella abortus.    
     
     
         30 . Use of any one of  claims 20 - 28 , wherein the pathogen selected from the group consisting of,
 (a)  Acinetobacter baumannii, Bacillus anthracis, Brucella abortus, Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia thailandensis, Citrobacter freundii, Corynebacterium jeikeium, Enterobacter  sp,  Enterobacter cloacae, Enterococcus faecium, Enterococcus gallinarum, Francisella tularensis, Klebsiella aerogenes, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria meningitides, Proteus mirabilis, Providencia stuartii, Serratia marcescens, Shigella  sp,  Staphylococcus haemolyticus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus bovis, Streptococcus constellatus, Streptococcus mitis, Streptococcus pyogenes, Streptococcus oralis, Streptococcus sanguis , Group C  Streptococcus , and  Yersinia pestis,      (b) drug-resistant strains of any pathogen of part (a); and   (c) and drug-resistant strains of  Staphylococcus aureus, Staphylococcus epidermis, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa , and  Haemophilus  influenza.   
     
     
         31 . Use any one of  claims 20 - 28 , wherein the pathogen is selected from the group consisting of  Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Stenotrophomonas maltophilia, Streptococcus pneumoniae , and drug-resistant strains thereof. 
     
     
         32 . Use of  claim 20 , wherein the pathogen is selected from the group consisting of  Burkholderia cepacia, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus , and drug-resistant strains thereof; and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         33 . Use of  claim 20 , wherein the pathogen is selected from the group consisting of  Burkholderia mallei, Burkholderia pseudomallei, Bacillus anthracis, Yersinia pestis, Francisella tularensis , and  Brucella abortus , and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-5-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-chloro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxymethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         34 . Use of  claim 20 , wherein the pathogen is selected from the group consisting of  Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Burkholderia cepacia, Haemophilus influenzae, Acinetobacter baumannii , and drug resistant strains thereof;
 and the compound is   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         35 . Use of  claim 20 , wherein the pathogen is selected from the group consisting of  Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus saprophyticus, Enterococcus faecalis, Enterococcus faecium, Enterococcus gallinarum, Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus agalactiae , Group C  Streptococcus, Streptococcus mitis, Streptococcus constellatus, Streptococcus oralis, Streptococcus bovis, Streptococcus sanguis, Corynebacterium jeikeium, Listeria monocytogenes, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Enterobacter  sp,  Serratia marcescens, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia, Proteus mirabilis, Shigella  sp,  Morganella morganii, Providencia stuartii, Neisseria meningitides, Haemophilus influenza, Moraxella catarrhalis, Acinetobacter baumannii, Citrobacter freundii , and drug resistant strains thereof; and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         36 . Use of  claim 20 , wherein the pathogen is selected from the group consisting of  Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Burkholderia cepacia, Haemophilus influenzae, Acinetobacter baumannii , and drug resistant strains thereof;
 and the compound is   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         37 . Use of  claim 20 , wherein the pathogen is Methicillin-resistant  Staphylococcus aureus  and the compound is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         38 . Use of any one of  claims 20 - 37 , wherein the compound is a pharmaceutically acceptable salt, and the pharmaceutically acceptable salt is a potassium salt. 
     
     
         39 . A compound of the formula, 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         R 1  is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8  haloalkyl, heterocyclyl, —OR 11 , —N(R 11 ) 2 , or —C(O)N(R 11 ) 2 , wherein each R 11  is independently hydrogen, C 1-8  alkyl, or C 1-8  haloalkyl; 
         R 2  is a C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, or heteroaryl, wherein the cycloalkyl and heteroaryl are optionally substituted with one to five groups that are each independently halogen, C 1-8  alkyl, —OR 21 , —N(R 21 ) 2 , or —C(O)OR 21 , wherein each R 21  is independently hydrogen or C 1-8  alkyl; 
         Y is heterocyclyl, aryl, or heteroaryl, each optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Y , or —C 1-8  alkyl-R Y , wherein 
         R Y  is nitro, cyano, —OR Y1 , —SR Y1 , —N(R Y1 ) 2 , —C(O)R Y1 , —C(O)OR Y1 , —C(O)N(R Y1 ) 2 , —OC(O)R Y1 , —OC(O)OR Y1 , —OC(O)N(R Y1 ) 2 , —N(R Y1 )C(O)R Y1 , —N(R Y1 )C(O)OR Y1 , —N(R Y1 )C(O)N(R Y1 ) 2 , —S(O) 2 R Y1 , —S(O) 2 OR Y1 , —S(O) 2 N(R Y1 ) 2 , —OS(O) 2 R Y1 , —OS(O) 2 OR Y1 , —OS(O) 2 N(R Y1 ) 2 , —N(R Y1 )S(O) 2 R Y1 , —N(R Y1 )S(O) 2 OR Y1 , or —N(R Y1 )S(O) 2 N(R Y1 ) 2 , wherein each R Y1  is independently hydrogen, C 1-8  alkyl, or C 1-8  haloalkyl; and 
         X is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8 haloalkyl, —OR X , —N(R X ) 2 , —C(O)R X , —C(O)OR X , or —C(O)N(R X ) 2 , wherein each R X  is independently hydrogen, C 1-8  alkyl, or C 1-8 haloalkyl, 
         for treating an infection caused by a pathogen selected from the group consisting of  Burkholderia mallei, Burkholderia pseudomallei, Burkholderia cepacia, Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella abortus, Burkholderia thailandensis, Acinetobacter baumannii, Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus epidermis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus , and drug-resistant strains thereof. 
       
     
     
         40 . The compound of  claim 39  that reduces the risk of contagion caused by an infection induced by a pathogen selected from the group consisting of  Burkholderia mallei, Burkholderia pseudomallei, Burkholderia cepacia, Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella abortus, Burkholderia thailandensis, Acinetobacter baumannii, Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus epidermis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus , and drug-resistant strains thereof, in an individual at risk of acquiring the infection by at least 5%, or at least 10%, or at least 15%, or at least 20%, or at least 30% or at least 40%, or at least 50%, or at least 60%, or at least 70% or at least 80%, or at least 90%, or more. 
     
     
         41 . The compound of  claim 39  selected from the group consisting of,
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid; 
 8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid; 
 8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid; 
 8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid; 
 8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid; 
 or a pharmaceutically acceptable salt thereof, 
 for treating an infection caused by a pathogen selected from the group consisting of  Burkholderia mallei, Burkholderia pseudomallei, Burkholderia cepacia, Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella abortus, Burkholderia thailandensis, Acinetobacter baumannii, Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus epidermis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes , Group C  Streptococcus , and drug-resistant strains thereof. 
 
     
     
         42 . The compound of any one of  claims 39 - 41  that is a potassium salt. 
     
     
         43 . A compound that is
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-5-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-chloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methoxy-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-sulfonamido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methyl-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-ureido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-dichloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-chloro-4-amino-5-methyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2,5-difluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-cyano-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-pyrrol-3-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-chloro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-methoxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-2-oxo-3,4-dihydro-1H-quinolin-7-yl)-1-cyclohexyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         44 . A compound of the formula, 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         R 1  is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8  haloalkyl, heterocyclyl, —OR 11 , —N(R 11 ) 2 , or —C(O)N(R 11 ) 2 , wherein each R 11  is independently hydrogen, C 1-8 alkyl, or C 1-8  haloalkyl; 
         R 2  is a C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, or heteroaryl, wherein the cycloalkyl and heteroaryl are optionally substituted with one to five groups that are each independently halogen, C 1-8  alkyl, —OR 21 , —N(R 21 ) 2 , or —C(O)OR 21 , wherein each R 21  is independently hydrogen or C 1-8  alkyl; 
         Z is a bicyclic heteroaryl, optionally substituted by one to five groups that are each independently halogen, C 1-8  alkyl, C 1-8  haloalkyl, C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, C 3-8 cycloalkyl(C 1-8 )alkyl, heterocyclyl(C 1-8 )alkyl, aryl(C 1-8 )alkyl, heteroaryl(C 1-8 )alkyl, —R Z , or —C 1-8  alkyl-R Z , wherein 
         R Z  is nitro, cyano, —OR Z1 , —SR Z1 , —N(R Z1 ) 2 , —C(O)R Z1 , —C(O)OR Z1 , —C(O)N(R Z1 ) 2 , —OC(O)R Z1 , —OC(O)OR Z1 , —OC(O)N(R Z1 ) 2 , —N(R Z1 )C(O)R Z1 , —N(R Z1 )C(O)OR Z1 , —N(R Z1 )C(O)N(R Z1 ) 2 , —S(O) 2 R Z1 , —S(O) 2 OR Z1 , —S(O) 2 N(R Z1 ) 2 , —OS(O) 2 R Z1 , —OS(O) 2 OR Z1 , —OS(O) 2 N(R Z1 ) 2 , —N(R Z1 )S(O) 2 R Z1 , —N(R Z1 )S(O) 2 OR Z1 , or —N(R Z1 )S(O) 2 N(R Z1 ) 2 , wherein each R Z1  is hydrogen, C 1-8  alkyl, or C 1-8  haloalkyl; and 
         X is hydrogen, halogen, cyano, C 1-8  alkyl, C 1-8 haloalkyl, —OR X , —N(R X ) 2 , —C(O)R X , —C(O)OR X , or —C(O)N(R X ) 2 , wherein each R X  is independently hydrogen, C 1-8  alkyl, or C 1-8 haloalkyl. 
       
     
     
         45 . A method for treating an infection comprising, providing to a patient infected by a gram-positive pathogen or gram-negative pathogen a therapeutically effective amount of a compound of  claim 44 . 
     
     
         46 . The method of  claim 45 , wherein the gram-negative pathogen or gram-positive pathogen is selected from the group consisting of  Acinetobacter baumannii, Bacillus anthracis, Brucella abortus, Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia thailandensis, Citrobacter freundii, Corynebacterium jeikeium, Enterobacter  sp,  Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Enterococcus gallinarum, Escherichia coli, Francisella tularensis, Haemophilus influenza, Klebsiella aerogenes, Klebsiella pneumoniae, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria meningitides, Proteus mirabilis, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Shigella  sp,  Staphylococcus aureus, Staphylococcus epidermis, Staphylococcus haemolyticus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus bovis, Streptococcus constellatus, Streptococcus mitis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus oralis, Streptococcus sanguis , Group C  Streptococcus, Yersinia pestis , and drug-resistant strains thereof. 
     
     
         47 . Use of a therapeutically effective amount of a compound of  claim 44  for treating an infection caused by a gram-positive pathogen or gram-negative pathogen. 
     
     
         48 . Use of  claim 47 , wherein the gram-positive pathogen or gram-negative pathogen is selected from the group consisting of  Acinetobacter baumannii, Bacillus anthracis, Brucella abortus, Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia thailandensis, Citrobacter freundii, Corynebacterium jeikeium, Enterobacter  sp,  Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Enterococcus gallinarum, Escherichia coli, Francisella tularensis, Haemophilus influenza, Klebsiella aerogenes, Klebsiella pneumoniae, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria meningitides, Proteus mirabilis, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Shigella  sp,  Staphylococcus aureus, Staphylococcus epidermis, Staphylococcus haemolyticus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus bovis, Streptococcus constellatus, Streptococcus mitis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus oralis, Streptococcus sanguis , Group C  Streptococcus, Yersinia pestis , and drug-resistant strains thereof. 
     
     
         49 . A compound that is
 1-cyclopropyl-8-(1H-indazol-5-yl)-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid;   8-(4-amino-2,5-difluorophenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid;   1-cyclopropyl-8-(4-hydroxyphenyl)-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salt thereof.   
     
     
         50 . A compound that is
 potassium 8-(4-amino-3-fluorophenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylate;   potassium 8-(6-aminopyridin-3-yl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylate; or   potassium 8-(5-(aminomethyl)furan-2-yl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid.   
     
     
         51 . A method for treating an infection comprising, providing to a subject infected by a pathogen selected from the group consisting of  Acinetobacter baumannii, Bacillus anthracis, Brucella abortus, Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia thailandensis, Citrobacter freundii, Corynebacterium jeikeium, Enterobacter  sp,  Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Enterococcus gallinarum, Escherichia coli, Francisella tularensis, Haemophilus influenza, Klebsiella aerogenes, Klebsiella pneumoniae, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria meningitides, Proteus mirabilis, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Shigella  sp,  Staphylococcus aureus, Staphylococcus epidermis, Staphylococcus haemolyticus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus bovis, Streptococcus  constellatus,  Streptococcus mitis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus oralis, Streptococcus sanguis , Group C  Streptococcus, Yersinia pestis , and drug-resistant strains thereof, a therapeutically effective amount of a compound selected from the group consisting of
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   or a pharmaceutically acceptable salts thereof,
 wherein the compound is provided to the subject as either 
   (a) an oral formulation that, when given orally in a mouse model, has one or more of
 (i) peak serum concentration (C max )&gt;0.15 μg/mL; 
 (ii) t max &lt;45 minutes; 
 (iii) half-life (t 1/2 )&gt;1 hour; and/or 
 (iv) oral bioavailability (F)&gt;40%; 
   (b) an intravenous formulation that, when given intravenously in a mouse model, has one or more of
 (i) an apparent volume of distribution (V d )&gt;5000 mL/kg; and/or 
 (ii) half-life (t 1/2 )≧1 hour. 
   
     
     
         52 . A potassium salt of a compound selected from the group consisting of:
 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-5-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-chloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methoxy-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-acetamido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-sulfonamido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-methylamino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-methyl-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-fluoro-4-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-ureido-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-dimethylamino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-dichloro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2-chloro-4-amino-5-methyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-aminomethyl-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-toluyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(piperazin-1-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[(3S)-3-amino-1-piperidyl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carbamoyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(2,5-difluoro-4-amino-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3,5-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-cyano-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-carboxy-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1,2,3,6-tetrahydro-pyridin-4-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(1H-pyrrol-3-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-fluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-chloro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-methoxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(4-hydroxymethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-fluoro-4-aminomethyl-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-(3-amino-2-oxo-3,4-dihydro-1H-quinolin-7-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;   8-[5-(aminomethyl)-2-furyl]-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid; and   8-(4-cyano-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid.   
     
     
         53 . A compound that is
 potassium 8-(3-fluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylate;   potassium 8-(6-amino-3-pyridyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylate;   potassium 8-(1H-indazol-5-yl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylate;   potassium 8-(3,6-difluoro-4-amino-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylate; or   potassium 8-(4-hydroxy-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylate.
Join the waitlist — get patent alerts

Track US2015141435A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.